Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Calliditas Therapeutics, Raises Price Target to $62

HC Wainwright & Co. analyst Edwin Zhang maintains Calliditas Therapeutics (NASDAQ:CALT) with a Buy and raises the price target from $52 to $62.
byBenzinga Newsdesk
December 20, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Edwin Zhang maintains Calliditas Therapeutics (NASDAQ:CALT) with a Buy and raises the price target from $52 to $62.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0